Vertex Pharmaceuticals - VRTX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $322.79
  • Forecasted Upside: 0.42%
  • Number of Analysts: 15
  • Breakdown:
  • 0 Sell Ratings
  • 6 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$321.45
▲ +0.43 (0.13%)

This chart shows the closing price for VRTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Vertex Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VRTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VRTX

Analyst Price Target is $322.79
▲ +0.42% Upside Potential
This price target is based on 15 analysts offering 12 month price targets for Vertex Pharmaceuticals in the last 3 months. The average price target is $322.79, with a high forecast of $374.00 and a low forecast of $280.00. The average price target represents a 0.42% upside from the last price of $321.45.

This chart shows the closing price for VRTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 15 contributing investment analysts is to buy stock in Vertex Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 14 buy ratings
  • 8 hold ratings
  • 0 sell ratings
8/7/2021
  • 0 strong buy ratings
  • 12 buy ratings
  • 7 hold ratings
  • 0 sell ratings
11/5/2021
  • 0 strong buy ratings
  • 10 buy ratings
  • 7 hold ratings
  • 0 sell ratings
2/3/2022
  • 0 strong buy ratings
  • 11 buy ratings
  • 7 hold ratings
  • 0 sell ratings
5/4/2022
  • 0 strong buy ratings
  • 11 buy ratings
  • 5 hold ratings
  • 0 sell ratings
8/2/2022
  • 0 strong buy ratings
  • 12 buy ratings
  • 5 hold ratings
  • 0 sell ratings
10/31/2022
  • 0 strong buy ratings
  • 11 buy ratings
  • 6 hold ratings
  • 0 sell ratings
12/30/2022
  • 0 strong buy ratings
  • 9 buy ratings
  • 6 hold ratings
  • 0 sell ratings
1/29/2023

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 6 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/24/2023Morgan StanleyBoost TargetEqual Weight$285.00 ➝ $286.00Low
1/19/2023Piper SandlerBoost TargetNeutral$293.00 ➝ $296.00Low
1/18/2023Canaccord Genuity GroupInitiated CoverageHold$311.00Low
1/17/2023SVB LeerinkUpgradeMarket Perform ➝ Outperform$374.00Low
12/19/2022Jefferies Financial GroupDowngradeBuy ➝ Hold$340.00Low
11/17/2022ArgusBoost TargetBuy$320.00 ➝ $340.00Low
11/1/2022GuggenheimBoost Target$318.00Low
11/1/2022Robert W. BairdBoost Target$280.00Low
10/28/2022Royal Bank of CanadaBoost TargetSector Perform$281.00 ➝ $288.00Low
10/28/2022BarclaysBoost TargetOverweight$307.00 ➝ $313.00Low
10/28/2022Morgan StanleyBoost TargetEqual Weight$253.00 ➝ $285.00Low
10/28/2022Wells Fargo & CompanyBoost TargetOverweight$305.00 ➝ $335.00Low
10/28/2022CowenBoost Target$315.00 ➝ $330.00Low
10/28/2022CowenBoost Target$315.00 ➝ $330.00Low
10/24/2022JPMorgan Chase & Co.Boost TargetOverweight$319.00 ➝ $327.00Low
10/16/2022Piper SandlerBoost Target$288.00 ➝ $293.00Low
8/16/2022Piper SandlerBoost TargetNeutral$256.00 ➝ $288.00Low
8/8/2022Morgan StanleyBoost TargetEqual Weight$250.00 ➝ $253.00Low
8/5/2022HC WainwrightBoost TargetBuy$275.00 ➝ $300.00Low
8/5/2022BarclaysBoost TargetOverweight$291.00 ➝ $307.00Low
7/26/2022Piper SandlerBoost TargetNeutral$242.00 ➝ $256.00Low
7/12/2022Cantor FitzgeraldInitiated CoverageOverweight$365.00N/A
6/13/2022CowenBoost TargetOutperform$305.00 ➝ $310.00Medium
6/13/2022ArgusBoost TargetBuy$275.00 ➝ $280.00High
6/13/2022CowenBoost Target$305.00 ➝ $310.00High
6/1/2022Maxim GroupUpgradeHold ➝ Buy$325.00Medium
5/23/2022SVB LeerinkInitiated CoverageMarket Perform$265.00High
5/6/2022Wells Fargo & CompanyBoost Target$300.00 ➝ $305.00Medium
5/6/2022Robert W. BairdDowngradeOutperform ➝ Neutral$250.00Medium
5/6/2022Piper SandlerLower Target$249.00 ➝ $242.00Medium
5/3/2022Morgan StanleyUpgradeUnderweight ➝ Equal Weight$250.00Medium
4/21/2022Piper SandlerBoost TargetNeutral$245.00 ➝ $249.00High
4/13/2022UBS GroupBoost Target$258.00 ➝ $325.00High
4/5/2022Wells Fargo & CompanyBoost TargetOverweight$270.00 ➝ $300.00N/A
4/4/2022OppenheimerBoost Target$305.00 ➝ $350.00Low
3/23/2022HC WainwrightReiterated RatingBuy$275.00High
2/3/2022Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$269.00Medium
1/27/2022Wolfe ResearchBoost TargetOutperform$271.00 ➝ $282.00Low
1/27/2022JPMorgan Chase & Co.Boost TargetOverweight$260.00 ➝ $288.00Low
1/27/2022Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$268.00 ➝ $269.00Low
1/27/2022Stifel NicolausBoost TargetHold$213.00 ➝ $222.00Low
1/27/2022Morgan StanleyBoost TargetUnderweight$203.00 ➝ $208.00Low
1/20/2022BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$202.00 ➝ $274.00Medium
12/23/2021Evercore ISIReiterated RatingBuy$265.00Low
12/8/2021Wells Fargo & CompanyInitiated CoverageOverweight$270.00Low
12/2/2021Royal Bank of CanadaBoost TargetFair Value ➝ Outperform$250.00 ➝ $265.00Low
11/18/2021BMO Capital MarketsInitiated CoverageMarket Perform$202.00Medium
11/18/2021Piper SandlerDowngradeOverweight ➝ Neutral$323.00 ➝ $218.00Low
11/3/2021Royal Bank of CanadaBoost TargetOutperform$246.00 ➝ $250.00High
9/9/2021Stifel NicolausDowngradeBuy ➝ Hold$244.00 ➝ $213.00Medium
9/7/2021Morgan StanleyDowngradeEqual Weight ➝ Underweight$202.00High
7/30/2021Morgan StanleyLower TargetEqual Weight$205.00 ➝ $202.00Low
7/30/2021Royal Bank of CanadaBoost TargetOutperform$246.00 ➝ $248.00Low
7/30/2021SVB LeerinkBoost TargetUnderperform$170.00 ➝ $175.00Low
7/30/2021Piper SandlerBoost TargetOverweight$261.00 ➝ $323.00Low
7/20/2021SVB LeerinkDowngradeMarket Perform ➝ Underperform$200.00 ➝ $170.00Low
7/19/2021Wolfe ResearchInitiated CoverageOutperform$252.00Low
6/30/2021Raymond JamesInitiated CoverageMarket PerformLow
6/14/2021Truist FinancialBoost TargetBuy$305.00 ➝ $331.00Low
6/14/2021Piper SandlerLower TargetOverweight$347.00 ➝ $261.00Low
6/14/2021SVB LeerinkLower TargetReduce ➝ Market Perform$250.00 ➝ $200.00Low
6/13/2021Evercore ISIReiterated RatingBuyLow
6/11/2021Stifel NicolausLower TargetBuy$277.00 ➝ $244.00High
6/11/2021The Goldman Sachs GroupLower TargetBuy$358.00 ➝ $307.00High
6/11/2021BarclaysLower TargetOverweight$302.00 ➝ $285.00High
6/11/2021Cantor FitzgeraldLower TargetOverweight$285.00 ➝ $281.00High
6/11/2021Morgan StanleyLower TargetEqual Weight$254.00 ➝ $205.00High
6/11/2021Robert W. BairdLower TargetOutperform$252.00 ➝ $240.00High
6/11/2021Royal Bank of CanadaLower TargetPositive ➝ Outperform$262.00 ➝ $242.00High
6/11/2021Daiwa Capital MarketsDowngradeOutperform ➝ Neutral$210.00High
5/3/2021Morgan StanleyBoost TargetEqual Weight$253.00 ➝ $254.00Low
4/26/2021Morgan StanleyBoost TargetEqual Weight$253.00 ➝ $254.00N/A
4/19/2021Morgan StanleyBoost TargetEqual Weight$251.00 ➝ $253.00Low
4/11/2021Royal Bank of CanadaReiterated RatingBuyLow
2/23/2021Robert W. BairdUpgradeNeutral ➝ Outperform$220.00 ➝ $252.00Medium
2/2/2021BMO Capital MarketsLower TargetOutperform$302.00 ➝ $284.00Low
2/2/2021Credit Suisse GroupLower TargetOutperform$285.00 ➝ $280.00Low
2/2/2021SVB LeerinkLower TargetMarket Perform$257.00 ➝ $250.00Low
2/2/2021Piper SandlerBoost TargetOverweight$307.00 ➝ $347.00Low
2/2/2021HC WainwrightLower TargetBuy$315.00 ➝ $275.00Low
1/19/2021Morgan StanleyBoost TargetEqual Weight$249.00 ➝ $251.00Low
12/30/2020Daiwa Capital MarketsInitiated CoverageOutperform$250.00N/A
12/11/2020JPMorgan Chase & Co.Reiterated RatingBuyLow
11/30/2020Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$247.00 ➝ $267.00Low
11/20/2020Sanford C. BernsteinInitiated CoverageOutperform$275.00Low
11/1/2020JPMorgan Chase & Co.Reiterated RatingBuyLow
10/30/2020Piper SandlerLower TargetOverweight$327.00 ➝ $307.00Low
10/30/2020Credit Suisse GroupLower TargetOutperform$292.00 ➝ $285.00Low
10/30/2020SVB LeerinkLower TargetMarket Perform$267.00 ➝ $257.00High
10/28/2020UBS GroupInitiated CoverageBuy$287.00Low
10/26/2020Needham & Company LLCReiterated RatingHoldMedium
10/19/2020Morgan StanleyLower TargetEqual Weight$281.00 ➝ $249.00Medium
10/15/2020Truist FinancialLower Target$330.00 ➝ $305.00High
10/15/2020SVB LeerinkLower TargetMarket Perform$283.00 ➝ $267.00High
10/13/2020Morgan StanleyLower TargetEqual Weight$300.00 ➝ $281.00Low
9/18/2020Maxim GroupReiterated RatingHoldHigh
8/24/2020SVB LeerinkBoost TargetNeutral ➝ Market Perform$274.00 ➝ $283.00Medium
7/31/2020Cantor FitzgeraldBoost TargetOverweight$293.00 ➝ $305.00High
7/31/2020SVB LeerinkBoost TargetMarket Perform$263.00 ➝ $274.00High
7/31/2020HC WainwrightReiterated RatingBuy$295.00 ➝ $315.00High
7/31/2020Piper SandlerBoost TargetOverweight$302.00 ➝ $327.00High
7/20/2020Credit Suisse GroupBoost TargetOutperform$298.00 ➝ $328.00High
7/16/2020CowenBoost TargetOutperform$265.00 ➝ $300.00Low
7/14/2020Jefferies Financial GroupBoost TargetBuy$295.00 ➝ $340.00High
7/8/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$277.00 ➝ $300.00Medium
7/2/2020The Goldman Sachs GroupBoost TargetPositive ➝ Conviction-Buy$290.00 ➝ $330.00Low
6/24/2020SunTrust BanksBoost TargetBuy$285.00 ➝ $330.00High
6/12/2020CitigroupBoost TargetTop Pick ➝ Buy$305.00 ➝ $325.00Low
5/15/2020ArgusBoost TargetBuy$270.00 ➝ $320.00High
5/1/2020CitigroupBoost TargetBuy$265.00 ➝ $305.00Medium
4/30/2020Credit Suisse GroupReiterated RatingBuy$298.00Medium
4/30/2020CfraBoost TargetBuy$286.00 ➝ $297.00Low
4/30/2020GuggenheimBoost TargetBuy$266.00 ➝ $290.00High
4/30/2020BMO Capital MarketsBoost TargetOutperform$279.00 ➝ $283.00High
4/30/2020Stifel NicolausBoost TargetBuy$275.00 ➝ $285.00High
4/30/2020OppenheimerBoost TargetOutperform$265.00 ➝ $305.00High
4/30/2020Morgan StanleyBoost TargetOverweight$258.00 ➝ $277.00High
4/30/2020SVB LeerinkBoost TargetMarket Perform$224.00 ➝ $263.00High
4/30/2020JMP SecuritiesBoost TargetMarket Outperform$255.00 ➝ $285.00High
4/30/2020HC WainwrightBoost TargetBuy$270.00 ➝ $295.00High
4/28/2020Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$250.00 ➝ $260.00High
4/27/2020Piper SandlerReiterated RatingBuy$300.00High
4/15/2020Morgan StanleyBoost TargetOverweight$251.00 ➝ $258.00Medium
3/27/2020Piper SandlerReiterated RatingBuy$300.00High
3/12/2020Wolfe ResearchInitiated CoverageOutperform$282.00High
3/11/2020Cantor FitzgeraldReiterated RatingOverweight$262.00 ➝ $275.00Medium
3/4/2020BarclaysInitiated CoverageOverweight$271.00High
3/3/2020CowenReiterated RatingBuy$260.00Medium
3/2/2020ArgusBoost TargetPositive ➝ Buy$248.00 ➝ $270.00High
2/2/2020Evercore ISIReiterated RatingHold$270.00Medium
1/31/2020Piper SandlerBoost Target$284.00 ➝ $300.00Medium
1/31/2020Bank of AmericaReiterated RatingBuy$250.00 ➝ $295.00High
1/31/2020Needham & Company LLCReiterated RatingHoldHigh
1/31/2020Morgan StanleyBoost TargetOverweight$250.00 ➝ $251.00Low
1/31/2020Stifel NicolausBoost TargetBuy$243.00 ➝ $275.00High
1/31/2020Royal Bank of CanadaBoost TargetOutperform$240.00 ➝ $260.00High
1/31/2020CfraBoost TargetBuy$237.00 ➝ $286.00High
1/31/2020Credit Suisse GroupBoost TargetOutperform$253.00 ➝ $258.00High
1/31/2020SunTrust BanksReiterated RatingBuy$285.00High
1/31/2020JPMorgan Chase & Co.Boost TargetOverweight$247.00 ➝ $260.00High
1/31/2020HC WainwrightBoost TargetBuy$220.00 ➝ $270.00High
1/31/2020Robert W. BairdDowngradeOutperform ➝ Neutral$210.00 ➝ $230.00High
1/14/2020JPMorgan Chase & Co.Reiterated RatingBuyLow
1/9/2020BMO Capital MarketsBoost Target$248.00 ➝ $268.00Low
1/8/2020OppenheimerBoost TargetOutperform$230.00 ➝ $265.00Low
1/6/2020Piper Jaffray CompaniesBoost TargetOverweight$247.00 ➝ $284.00N/A
1/2/2020Raymond JamesDowngradeOutperform ➝ Market PerformLow
12/18/2019JPMorgan Chase & Co.Boost TargetOverweight$218.00 ➝ $247.00Low
12/16/2019ArgusBoost TargetBuy$248.00Medium
12/13/2019Credit Suisse GroupUpgradeBuy$231.00Low
11/20/2019BMO Capital MarketsBoost TargetOutperform ➝ Positive$248.00Low
11/19/2019CowenReiterated RatingBuyLow
11/19/2019GuggenheimUpgradeNeutral ➝ Buy$252.00High
11/12/2019SunTrust BanksInitiated CoverageBuy$235.00Medium
11/4/2019Credit Suisse GroupReiterated RatingBuy$228.00Low
11/1/2019Maxim GroupReiterated RatingHoldHigh
10/31/2019Piper Jaffray CompaniesBoost TargetOverweight$230.00 ➝ $247.00High
10/22/2019Credit Suisse GroupBoost TargetOverweight$213.00 ➝ $221.00Low
10/22/2019SVB LeerinkBoost TargetMarket Perform$186.00 ➝ $203.00High
10/22/2019CitigroupBoost TargetBuy$205.00 ➝ $225.00High
10/21/2019BMO Capital MarketsSet TargetBuy$232.00Medium
10/21/2019Jefferies Financial GroupSet TargetBuy$220.00Medium
10/21/2019CowenSet TargetBuy$220.00Medium
10/21/2019Robert W. BairdSet TargetBuy$210.00Medium
10/21/2019JPMorgan Chase & Co.Set TargetBuy$218.00Medium
10/16/2019Bank of AmericaInitiated CoverageBuy$220.00Medium
9/23/2019Jefferies Financial GroupBoost Target$210.00 ➝ $220.00Medium
9/6/2019Morgan StanleyBoost TargetOverweight$215.00 ➝ $240.00Low
9/3/2019The Goldman Sachs GroupUpgradeNeutral ➝ Buy$226.00 ➝ $254.00High
8/12/2019Royal Bank of CanadaSet TargetBuy$213.00Low
8/2/2019Maxim GroupReiterated RatingHoldLow
8/1/2019Credit Suisse GroupBoost TargetOutperform$209.00 ➝ $213.00Low
8/1/2019Piper Jaffray CompaniesBoost TargetOverweight$217.00 ➝ $230.00Low
8/1/2019Stifel NicolausBoost TargetBuy$205.00 ➝ $211.00Low
8/1/2019JPMorgan Chase & Co.Reiterated RatingBuy$212.00High
8/1/2019HC WainwrightReiterated RatingBuy$220.00High
8/1/2019Needham & Company LLCDowngradeBuy ➝ HoldHigh
7/31/2019CowenSet TargetBuy$220.00N/A
6/2/2019JPMorgan Chase & Co.Reiterated RatingBuyLow
5/23/2019The Goldman Sachs GroupReiterated RatingBuy$220.00Low
5/23/2019CitigroupReiterated RatingBuy ➝ Buy$205.00Low
5/20/2019Credit Suisse GroupInitiated CoverageOutperform$209.00 ➝ $209.00Medium
5/1/2019Needham & Company LLCReiterated RatingBuy$195.00Low
5/1/2019JPMorgan Chase & Co.Reiterated RatingBuy$209.00High
4/30/2019CowenReiterated RatingBuy$220.00High
4/11/2019Evercore ISIInitiated CoverageIn-Line$183.00Low
3/26/2019William BlairUpgradeMarket Perform ➝ Outperform$183.85Medium
3/19/2019SVB LeerinkDowngradeOutperform ➝ Market Perform$185.40Medium
3/7/2019OppenheimerBoost TargetOutperform ➝ Outperform$200.00 ➝ $230.00Low
3/6/2019CowenReiterated RatingBuy$220.00Medium
3/6/2019Maxim GroupReiterated RatingHoldMedium
2/6/2019BMO Capital MarketsBoost TargetOutperform$234.00High
2/6/2019Maxim GroupDowngradeBuy ➝ HoldHigh
1/4/2019CitigroupLower TargetBuy ➝ Buy$206.00 ➝ $205.00Medium
1/2/2019Raymond JamesDowngradeOutperform ➝ Market Perform$165.71Low
12/19/2018Morgan StanleyLower TargetOverweight ➝ Overweight$211.00 ➝ $210.00High
12/17/2018GuggenheimInitiated CoverageNeutralMedium
12/17/2018Cantor FitzgeraldReiterated RatingBuy$217.00High
11/27/2018OppenheimerSet TargetBuy$200.00High
11/27/2018Cantor FitzgeraldReiterated RatingBuy$217.00Low
10/26/2018Piper Jaffray CompaniesLower TargetOverweight$217.00Medium
10/26/2018HC WainwrightUpgradeNeutral ➝ Buy$220.00High
10/25/2018BMO Capital MarketsLower TargetOutperform$204.00 ➝ $192.00High
10/25/2018Raymond JamesSet TargetBuy$211.00 ➝ $201.00High
10/24/2018JPMorgan Chase & Co.Reiterated RatingBuyMedium
10/2/2018Raymond JamesInitiated CoverageBuyLow
10/1/2018Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$217.00Medium
8/28/2018ArgusBoost TargetBuy ➝ Average$200.00High
8/7/2018Stifel NicolausBoost TargetBuy$182.00 ➝ $200.00Medium
7/30/2018CitigroupBoost TargetBuy ➝ Buy$203.00 ➝ $206.00Medium
7/26/2018Royal Bank of CanadaReiterated RatingBuy$203.00Medium
7/26/2018UBS GroupBoost TargetNeutral ➝ Neutral$183.00 ➝ $188.00High
7/26/2018Morgan StanleyBoost TargetOverweight ➝ Overweight$207.00 ➝ $211.00High
7/26/2018OppenheimerBoost TargetOutperform$180.00 ➝ $200.00High
7/26/2018Piper Jaffray CompaniesBoost TargetOverweight$230.00High
7/26/2018BMO Capital MarketsBoost TargetOutperform$204.00High
7/16/2018Jefferies Financial GroupBoost TargetBuy$210.00Low
7/1/2018JPMorgan Chase & Co.Reiterated RatingBuyLow
6/12/2018ArgusSet TargetBuy ➝ Buy$172.00Low
4/27/2018CowenReiterated RatingBuy$200.00Low
4/27/2018Morgan StanleyBoost TargetOverweight ➝ Overweight$200.00 ➝ $207.00Low
4/27/2018Maxim GroupReiterated RatingBuy$200.00High
3/5/2018Maxim GroupBoost TargetBuy ➝ Buy$195.00 ➝ $200.00Medium
2/23/2018ArgusSet TargetBuy ➝ Buy$194.00High
2/13/2018JMP SecuritiesReiterated RatingMarket Outperform ➝ Outperform$200.00 ➝ $211.00Low
2/13/2018Credit Suisse GroupBoost TargetOutperform ➝ Outperform$195.00 ➝ $196.00Low
2/13/2018HC WainwrightReiterated RatingHold$103.00Low
2/2/2018Morgan StanleyBoost TargetOverweight ➝ Overweight$198.00 ➝ $200.00Medium
2/1/2018Bank of AmericaBoost TargetBuy ➝ Buy$180.00 ➝ $197.00High
2/1/2018HC WainwrightReiterated RatingHold$103.00High
2/1/2018CitigroupReiterated RatingBuyHigh
2/1/2018BMO Capital MarketsBoost TargetOutperform ➝ Buy$184.00 ➝ $191.00High
2/1/2018SVB LeerinkReiterated RatingOutperform$175.00 ➝ $190.00High
2/1/2018Royal Bank of CanadaBoost TargetOutperform$200.00High
2/1/2018Jefferies Financial GroupReiterated RatingBuy$195.00High
2/1/2018BarclaysBoost TargetOverweight ➝ Overweight$180.00 ➝ $200.00High
1/31/2018Maxim GroupReiterated RatingBuy$195.00Low
(Data available from 1/29/2018 forward)

News Sentiment Rating

0.74 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 8 very positive mentions
  • 19 positive mentions
  • 4 negative mentions
  • 3 very negative mentions
7/3/2022
  • 10 very positive mentions
  • 21 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
8/2/2022
  • 9 very positive mentions
  • 41 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
9/1/2022
  • 9 very positive mentions
  • 17 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
10/1/2022
  • 14 very positive mentions
  • 35 positive mentions
  • 9 negative mentions
  • 0 very negative mentions
10/31/2022
  • 11 very positive mentions
  • 33 positive mentions
  • 1 negative mentions
  • 3 very negative mentions
11/30/2022
  • 12 very positive mentions
  • 19 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
12/30/2022
  • 16 very positive mentions
  • 15 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
1/29/2023

Current Sentiment

  • 16 very positive mentions
  • 15 positive mentions
  • 2 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Vertex Pharmaceuticals logo
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.
Read More

Today's Range

Now: $321.45
Low: $319.58
High: $323.67

50 Day Range

MA: $304.49
Low: $283.23
High: $321.48

52 Week Range

Now: $321.45
Low: $225.28
High: $324.75

Volume

1,288,678 shs

Average Volume

1,266,574 shs

Market Capitalization

$82.51 billion

P/E Ratio

25.35

Dividend Yield

N/A

Beta

0.46

Frequently Asked Questions

What sell-side analysts currently cover shares of Vertex Pharmaceuticals?

The following Wall Street analysts have issued stock ratings on Vertex Pharmaceuticals in the last twelve months: Argus, Barclays PLC, Canaccord Genuity Group Inc., Cantor Fitzgerald, Cowen Inc, Cowen Inc., Guggenheim, HC Wainwright, Jefferies Financial Group Inc., JPMorgan Chase & Co., Maxim Group, Morgan Stanley, Oppenheimer Holdings Inc., Piper Sandler, Robert W. Baird, Royal Bank of Canada, StockNews.com, SVB Leerink LLC, UBS Group AG, and Wells Fargo & Company.
View the latest analyst ratings for VRTX.

What is the current price target for Vertex Pharmaceuticals?

19 Wall Street analysts have set twelve-month price targets for Vertex Pharmaceuticals in the last year. Their average twelve-month price target is $322.79, suggesting a possible upside of 0.4%. SVB Leerink LLC has the highest price target set, predicting VRTX will reach $374.00 in the next twelve months. Robert W. Baird has the lowest price target set, forecasting a price of $280.00 for Vertex Pharmaceuticals in the next year.
View the latest price targets for VRTX.

What is the current consensus analyst rating for Vertex Pharmaceuticals?

Vertex Pharmaceuticals currently has 6 hold ratings and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe VRTX will outperform the market and that investors should add to their positions of Vertex Pharmaceuticals.
View the latest ratings for VRTX.

What other companies compete with Vertex Pharmaceuticals?

How do I contact Vertex Pharmaceuticals' investor relations team?

Vertex Pharmaceuticals' physical mailing address is 50 NORTHERN AVENUE, BOSTON MA, 02210. The pharmaceutical company's listed phone number is (617) 341-6100 and its investor relations email address is [email protected] The official website for Vertex Pharmaceuticals is www.vrtx.com. Learn More about contacing Vertex Pharmaceuticals investor relations.